Shots: Shots:

• Alexion to acquire all shares of Portola’s common stock at $18/ share in cash with a premium of 132%. Alexion will be acquiring cash currently on Portola’s balance sheet- net of debt of ~$215M that will become due upon closing. The actual amounts will be determined following the closure of the transaction
• The transaction is expected to be closed in Q3’20. The acquisition will expand Alexion’s hematology- neurology and critical care commercial portfolio with the addition of Portola’s Andexxa/ Ondexxya
• Andexxa [coagulation factor Xa (recombinant)- inactivated-zhzo]- marketed as Ondexxya in EU- is the first and only approved Factor Xa inhibitor reversal agent- and has demonstrated transformative clinical value by rapidly reversing the effects rivaroxaban and apixaban in severe and uncontrolled bleeding

Click here ­to­ read full press release/ article | Ref: Alexion | Image: Portola